The arrival of the Retatrutide vial marks a significant breakthrough in the approach to metabolic regulation. This groundbreaking medication combines two distinct mechanisms – agonist of the GLP-1 site and reduction of the DPP-4 enzyme – suggesting a distinctive method for addressing excess weigh